* patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (quinine, tafenoquine, hydroxychloroquine, mefloquine). * history of qt prolongation (qtc ≥ 500 ms) or qtc ≥ 500msec at screening or bradycardia \< 50/mn * current use of loop diuretics and potassium supplementation or documented history of hypokalemia or hypokalemia \< 3.5mmol/l at screening * prior allogeneic bone marrow transplantation or solid organ transplant in the past. * pregnant or breastfeeding patient, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of study drugs.

* patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (quinine, tafenoquine, hydroxychloroquine, mefloquine). * history of qt prolongation (qtc ≥ 500 ms) or qtc ≥ 500msec at screening or bradycardia \< 50/mn * current use of loop diuretics and potassium supplementation or documented history of hypokalemia or hypokalemia \< 3.5mmol/l at screening * prior allogeneic bone marrow transplantation or solid organ transplant in the past. * pregnant or breastfeeding patient, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of study drugs.

- patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (quinine, tafenoquine, hydroxychloroquine, mefloquine). - history of qt prolongation (qtc ≥ 500 ms) or qtc ≥ 500msec at screening or bradycardia < 50/mn - current use of loop diuretics and potassium supplementation or documented history of hypokalemia or hypokalemia < 3.5mmol/l at screening - prior allogeneic bone marrow transplantation or solid organ transplant in the past. - pregnant or breastfeeding patient, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of study drugs.

- patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (quinine, tafenoquine, hydroxychloroquine, mefloquine). - history of qt prolongation (qtc ≥ 500 ms) or qtc ≥ 500msec at screening or bradycardia < 50/mn - current use of loop diuretics and potassium supplementation or documented history of hypokalemia or hypokalemia < 3.5mmol/l at screening - prior allogeneic bone marrow transplantation or solid organ transplant in the past. - pregnant or breastfeeding patient, or expecting to conceive children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of study drugs.